AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT05550857 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: eccentric resistance exercise
Description: The subject will lying prone on a treatment table. One end of eccentric resistance band will tie around the mid of the foot of indvidual, the other end of the resistance band will be attach to the table and the band is adjusted so that it will tight and there will be no slack present in it. It will provide a smooth eccentric resistance throughout the dorsiflexion range
Study NCT05294497 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Product D
Description: Flavor variant P1313014 of a nicotine pouch product with 4 mg of nicotine
Study NCT05550857 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: myofascial release
Description: The subject will lye prone on a treatment table. Deep longitudinal massage with the help of both thumbs reinforcing eachother will be given on the subject's calf muscles.
Study NCT05294497 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Product N
Description: Nicorette® White Ice Mint 4 mg nicotine gum
Study NCT06243809 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Linagliptin 5 mg Oral Tablet
Description: Linagliptin 5 mg Oral Tablet
Study NCT06243809 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Trajenta 5 MG Oral Tablet
Description: Linagliptin 5 mg Oral Tablet (Trajenta )
Study NCT06243809 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Trajenta 5 MG Oral Tablet
Description: Linagliptin 5 mg Oral Tablet (Trajenta )
Study NCT06306040 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nalbuphine Versus Magnesium Sulfate
Description: Nalbuphine is a synthetic opioid receptor agonist-antagonist (agonist К receptor, antagonistic part μ receptor) that can produce a central analgesic effect and partial sedation. Nalbuphine is a medication that is indicated for moderate to severe pain where the patient requires an opioid agent, and other alternative treatments have been insufficient. The inhibitory effect of nalbuphine on respiration is slight and it has a capping effect. Owing to these advantages, it is widely used in pediatric surgical analgesia.~Magnesium sulphate, an antagonist of N-methyl-D-aspartate (NMDA) glutamate receptors, has been reported to improve hypo-magnesia and pre-eclampsia. Recently, magnesium sulphate has been gradually used as an adjuvant for sedation and analgesia during general anesthesia. Magnesium sulphate is a medication used to manage and treat multiple clinical conditions.
Study NCT05819424 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Yeast Fermentate (EpiCor)
Description: Dietary Supplement: Yeast Fermentate (EpiCor): Postbiotic whole food fermentate made using yeast. Composed of proteins, polyphenols, vitamins, minerals, amino acids, polysaccharides, fibre, and other nutrients.~Placebo: Substance with no therapeutic value to facilitate blinding
Study NCT05014035 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Resistance Exercise
Description: This is an 8-week exercise program, delivered using a hybrid approach of in-person, in-home supervised exercise, and virtual delivery of exercise via zoom. Individuals will participate in resistance exercise 3 days per week for 8 weeks.
Study NCT04623554 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Prehabilitation program
Description: The prehabilitation program includes combined high-intensity interval training on a cycle ergometer and machine-based resistance exercise of large muscle groups supervised by a physiotherapist. Exercise sessions will take place in physiotherapy departments at local hospitals or in municipality rehabilitation centres 3 times a week during the neoadjuvant chemotherapy period and ending in the week before breast surgery (maximum estimated 29 weeks depending on number of chemotherapy cycles, dose delays and time of breast surgery). Participants will be screened for psychological distress four times and in case of moderate-severe distress be advised to visit the local Cancer Society Support Center where participants will be assessed and offered free services based on their psychosocial needs and available offers. Participation will be monitored.
Study NCT05294497 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Product E
Description: Flavor variant P1313015 of a nicotine pouch product with 8 mg of nicotine
Study NCT05212467 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: AIR-program
Description: This is a guided self management program that is added on the treatment as usual.
Study NCT05212467 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: HUS Internet therapy
Description: This is a guided self management program that is added on the treatment as usual.
Study NCT05212467 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Treatment as usual
Description: The patients receive routine care from their physician which may include drugs, visits or rehabilitation
Study NCT05212467 — intervention group
Intervention type: BEHAVIORAL
Group type: PLACEBO_COMPARATOR
Intervention: Treatment as usual
Description: The patients receive routine care from their physician which may include drugs, visits or rehabilitation
Study NCT05575024 — intervention group
Intervention type: DEVICE
Intervention: oXiris membrane
Description: Perform continuous renal replacement therapy with oXiris membrane
Study NCT05575024 — intervention group
Intervention type: DEVICE
Intervention: Polysulfone membrane
Description: Perform continuous renal replacement therapy with polysulfone membrane
Study NCT06396689 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Synbiotic
Description: The capsule contains Lactobacillus helveticus R0052, Bifidobacterium infantis R0033, and Bifidobacterium bifidum R0071 (3 billion bacteria per capsule), as well as zinc oxide, potato starch fructooligosaccharides, coating agent, methyl hydroxypropyl cellulose, anti-caking agent and magnesium stearat
Study NCT06253455 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: tested product
Description: application twice a day of the tested product (in the morning and evening) and a sunscreen (in the morning and at midday) to the face for 3 months
Study NCT06179810 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Baduanjin exercise
Description: Baduanjin exercise
Study NCT04776616 — intervention group
Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: Exposure to white LED light
Description: Participants will be exposed to white LED strip lights in a dark room for 2 hours a day
Study NCT05783843 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Pictorial Warnings
Description: Participants will be shown 6 waterpipe tobacco packages with 6 different pictorial warnings about the health harms of waterpipe smoking. The order of the 6 packages within this trial arm will be randomized. Study investigators developed a fictitious waterpipe tobacco brand to be used in this study and designed the warnings for this arm.
Study NCT04776616 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Exposure to green LED light
Description: Participants will be exposed to green LED strip lights in a dark room for 2 hours a day
Study NCT04520152 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: FreeFlowMedical Lung Tensioning Device
Description: Bronchoscopic lung tensioning device implantation
Study NCT05783843 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Text Warnings
Description: Participants will be shown 6 waterpipe tobacco packages with 6 different text-only warnings about the health harms of waterpipe smoking. The order of the 6 packages within this trial arm will be randomized. Study investigators developed a fictitious waterpipe tobacco brand to be used in this study and designed the warnings for this arm.
Study NCT05783843 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: No Warnings (Control)
Description: Participants will be shown a single package without a warning. Study investigators developed a fictitious waterpipe tobacco brand to be used in this study.
Study NCT06366490 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Innocell Autologous Cellular Immunotherapy
Description: Innocell Autologous Cellular Immunotherapy
Study NCT05292521 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Best Practice
Description: Receive usual care
Study NCT05292521 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Informational Intervention
Description: Receive QOL fact sheet
Study NCT05292521 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Questionnaire Administration
Description: Ancillary studies
Study NCT05292521 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Questionnaire Administration
Description: Ancillary studies
Study NCT05525455 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TT-816
Description: TT-816 is a novel, oral cannabinoid CB2 receptor antagonist acting as an immune checkpoint inhibitor for the treatment of a broad range of solid tumors
Study NCT05525455 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: A PD-1 inhibitor
Description: Programmed death receptor-1 (PD 1)-blocking antibody
Study NCT05784194 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Intervention for correct discharge medication list
Description: As above
Study NCT04911166 — intervention group
Intervention type: COMBINATION_PRODUCT
Group type: EXPERIMENTAL
Intervention: Atezolizumab and Interleukin-12 Gene Therapy
Description: To determine the safety and tolerability of the atezolizumab and ADV/IL-12 gene therapy combination in patients with metastatic NSCLC who have disease progression after a prior line of either single agent immunotherapy or a regimen of chemoimmunotherapy.
Study NCT04815993 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SYN-020 delayed release capsule
Description: SYN-020, is an opaque, white, size 3 HPMC capsule for oral administration containing enteric-coated, delayed-release pellets.
Study NCT06396689 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: The capsule contains zinc oxide, coating agent, methyl hydroxypropyl cellulose, anti-caking agent and magnesium stearat
Study NCT06403553 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: Fecal Calprotectin
Description: Fecal Calprotectin measurement on days 1and 3
Study NCT05336734 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Psychotherapy
Description: see group description
Study NCT05223179 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: CODA-VAX H1N1
Description: Intramuscular Live Attenuated Influenza H1N1 Vaccine
Study NCT05223179 — intervention group
Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Flucelvax Quad
Description: Licensed Seasonal Injectable Influenza Vaccine
Study NCT05223179 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Saline
Description: Saline
Study NCT05993429 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: The sampling method selected in patients with suspected hilar cholangiocarcinoma
Description: The appropriate sampling approach was selected as EUS-FNA/B or ERCP with or without POCS-TB based on experts' overall evaluation. This study will compare the histopathological diagnosis of the selected sampling method with the final diagnosis.
Study NCT04763759 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TRL1068, a human monoclonal antibody
Description: A human IgG1κ (G1m1,17 (z,a); Km3 allotype) monoclonal antibody
Study NCT05788419 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: sonography
Description: imaging method, functional test of hip joint
Study NCT04774588 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: VSI streamer and Microsoft Hololens 2 classed as a Class III device by Health Canada.
Description: 1.1 Description of VSI streamer device and software The VSI Streamer is a box that can be connected to ultrasound, endoscope, microscope, laparoscope and other devices via HDMI connection. The view of the imaging devices, which is conventionally displayed on a monitor, is transmitted wirelessly and in real time to the Mixed Reality HoloLens 2 (Microsoft Inc.) and appears as a virtual monitor that can be flexibly moved and positioned in space. Since this is Mixed Reality, the real environment remains visible. If required, several virtual monitors can be streamed into the Mixed Reality glasses at the same time
Study NCT04774588 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: VSI streamer and Microsoft Hololens 2 classed as a Class III device by Health Canada.
Description: 1.1 Description of VSI streamer device and software The VSI Streamer is a box that can be connected to ultrasound, endoscope, microscope, laparoscope and other devices via HDMI connection. The view of the imaging devices, which is conventionally displayed on a monitor, is transmitted wirelessly and in real time to the Mixed Reality HoloLens 2 (Microsoft Inc.) and appears as a virtual monitor that can be flexibly moved and positioned in space. Since this is Mixed Reality, the real environment remains visible. If required, several virtual monitors can be streamed into the Mixed Reality glasses at the same time
Study NCT05203211 — intervention group
Intervention type: PROCEDURE
Intervention: Testicular sperm extraction (TESE)
Description: During the procedure, the testis is exposed through a small incision and one or more biopsies are taken blindly. A vertical incision is made in the median raphe, skin, dartos and tunica vaginalis to expose tunica albuginea. The tunica albuginea is incised for about 4 mm at upper pole near the head of epididymis.
Study NCT05594498 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: StrataXRT
Description: StrataXRT is a silicone-based film-forming topical gel that may help in reducing radiation dermatitis.
Study NCT05236452 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Training for traditional and modern care providers
Description: The intervention arm includes training for traditional and modern care providers, patient education, screening, and referring to TB suspected cases plus the usual care. The training will be provided three times which will be delivered every three months. In the first round, traditional practitioners will be trained for 5 days. In this round, the training will be also delivered to modern health care providers on how to communicate and work with traditional care providers for 2-day. Then, a one-day interactive discussion session will be prepared for both traditional and modern care providers. In the second round and third rounds, one-day training will be carried out at three and six months. TB suspected cases at traditional foster and holy water and patients who need spiritual support from health care providers will be screened every case in every day for one year. Referring to TB suspected cases will also apply for every case every day for one year
Study NCT05236452 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Training for traditional and modern care providers
Description: The intervention arm includes training for traditional and modern care providers, patient education, screening, and referring to TB suspected cases plus the usual care. The training will be provided three times which will be delivered every three months. In the first round, traditional practitioners will be trained for 5 days. In this round, the training will be also delivered to modern health care providers on how to communicate and work with traditional care providers for 2-day. Then, a one-day interactive discussion session will be prepared for both traditional and modern care providers. In the second round and third rounds, one-day training will be carried out at three and six months. TB suspected cases at traditional foster and holy water and patients who need spiritual support from health care providers will be screened every case in every day for one year. Referring to TB suspected cases will also apply for every case every day for one year
Study NCT05947695 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Palliative and Survivorship Care Model
Description: The standard of care comparator arm is usual clinical care using NCCN guidelines and evidence-based practice for palliative and survivorship care.
Study NCT05947695 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Palliative and Survivorship Care Model
Description: The standard of care comparator arm is usual clinical care using NCCN guidelines and evidence-based practice for palliative and survivorship care.
Study NCT04694794 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Educational Brochure
Description: Participants will be provided with Education Brochure developed by the study team to provide information to patients about managing side effects related to chemotherapy
Study NCT05375786 — intervention group
Intervention type: BIOLOGICAL
Intervention: Vaccination completion status
Description: the relation between vaccination completion status and the target population
Study NCT04923737 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Dexmedetomidine
Description: patients will receive a loading dose of IV Dexmedetomidine1μg/kg slowly just before induction of anesthesia, then Dexmedetomidine infusion started at a rate of 0.5μg/kg/h.
Study NCT04923737 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: 0.9% sodium chloride
Description: patients will receive an equal volume of 0.9% sodium chloride (both the loading, and the infusion
Study NCT05061771 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: nomacopan (rVA576)
Description: Nomacopan an inhibitor of complement C5 and LTB4
Study NCT05061771 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo
Study NCT05846945 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Threshold inspiratory muscle trainer device
Description: The threshold inspiratory muscle trainer (IMT) device offers resistance to respiration through the spring-loaded valve.
Study NCT05846945 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Adjusting mechanical ventilator trigger sensitivity
Description: modifying the mechanical ventilator trigger sensitivity so that patients can only initiate inspiratory flow by producing more negative intrathoracic pressure
Study NCT05846945 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Chest physiotherapy
Description: Conventional chest physiotherapy
Study NCT05846945 — intervention group
Intervention type: OTHER
Group type: SHAM_COMPARATOR
Intervention: Chest physiotherapy
Description: Conventional chest physiotherapy
Study NCT04707001 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Catheterization based on ultrasound
Description: Bladder volume ultrasound
Study NCT04707001 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Catheterization based on evaluation of symptoms
Description: Ask for symptoms: Need to urinate, lower abdominal pain
Study NCT04527094 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: Prediction of postoperative respiratory failure using a machine learning
Description: The performance of a machine learning model to predict postoperative respiratory failure after general anesthesia within postoperative day 7 was tested prospectively.
Study NCT04163042 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: 12-week videoconferencing behavioural support intervention to promote physical activity behaviour
Description: Participants in Group A will receive six real-time, 1-on-1 60-minute sessions led by a physical activity counsellor over a 12-week period. Sessions will be delivered via videoconferencing and will aim to provide young adult cancer survivors with support as well as the knowledge, skills, and confidence to identify and overcome challenges to engaging in physical activity in order to increase physical activity behaviour and enhance patient-reported outcomes.
Study NCT05797727 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: LifeChamps Platform HCP
Description: Healthcare professionals that will participate in the study will be introduced will have access to the LifeChamps Dashboard, which will display the data monitored from the patients, thus potentially facilitating patients' follow-up between clinical consultations. The LC Dashboard will provide pseudonymised information regarding the patients' physical activity and PROMs for the purpose of the pilot feasibility trial. They will not be able to view real time processed information, such as risk of frailty, QoL, risk of dependency and psychological condition, from the LIFECHAMPS analytics engine. They will be shown the anonymised outputs of the engine per patient and asked their opinions on the usability, acceptability and on whether such information would have helped better manage their patients' supportive care.
Study NCT05797727 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: LifeChamps Platform
Description: Participants will be asked to provide 5 endpoints (PROMS) and will be provided with the study equipment, i.e., a mobile app, smartwatch, smart scale, location home sensor, a smart plug, and a micro-computer, with which they will need to interact with the devices for three months. Specifically, participants should wear the activity tracker wristband (Fitbit Charge 4) as much as possible. Additionally, participants should use the smart scale to weigh themselves and the mobile app to fill in selected PROMs monthly, while the ambient home sensors will be passively collecting information about their everyday living during these three months. At the end of the 3 month period, the participants will return the devices and will be asked to provide the 5 endpoints and their opinions regarding the usability and acceptability of the platform using structured questionnaires